Condition: Myocardial Injury · Sponsor: The University of Hong Kong
This is an investigator initiated, multi-center, open-labelled, superiority randomized controlled trial of 372 patients undergoing elective non-cardiac surgery. Recruited patients will be randomized in a 2:1 ratio to receive single subcutaneous dose of Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RAs) 1 to 14 days prior to surgery or receive routine care. Dulaglutide (Trulicity; Eli Lilly, USA) is chosen as GLP-1 Receptor Agonists investigational drug for this study. Apart from peri-operative routine care, all recruited subjects will undergo physical, respiratory and cardiac assessments including electrocardiography and blood check including cardiac enzymes. Myocardial injury, cardiovascular outcomes and safety will be assessed and evaluated for efficacy and safety of this prophylactic measurement for the reduction of myocardial injury after non-cardiac surgery.
This description comes directly from the study's public registry record.
Chun Ka Wong, Clinical Assistant Professor · +852 2255 3597 · wongeck@hku.hk
Lily Hung, Master · +852 2255 4169 · nga98@hku.hk
Always discuss trial participation with your own doctor first.
| Duchess of Kent Children's Hospital at Sandy Bay | Hong Kong, Hong Kong SAR, China | Not Yet Recruiting |
| Queen Mary Hospital | Hong Kong, Hong Kong SAR, China | Recruiting |
| Tung Wah Hospital | Hong Kong, Hong Kong SAR, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06324461